As expected the addition of PDGFRβ inhibitor Nilotinib with MEK1/2-JAK2 inhibition in triple combination therapy significantly suppressed the tumor growth compared to the MEK1/2-JAK2 double combination therapy due to induction of apoptosis, as evident by Apoptag staining (Fig. 5c-e). Here, JAK2 is linked to neoplasm.